REZUROCK belumosudil

Drug Class

ROCK2 inhibitor

Mechanism

Inhibits Rho-associated coiled-coil kinase 2 (ROCK2), regulating pro-inflammatory Th17 and regulatory Treg cell balance, and downregulating pro-fibrotic signaling.

Approved Indication

Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

What This Means For Patients

REZUROCK is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2021) — Sources
• NMPA — Approved (2023) — Sources

Pivotal Clinical Evidence

• ROCKstar — Cutler et al., Blood 2021 (NCT03640481) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214701s000lbl.pdf
• https://www.nmpa.gov.cn/